title: The selective serotonin reuptake inhibitors controversy in the treatment of depression in children.
abstract: Antidepressants are widely prescribed for children and adolescents, although data regarding their safety and efficacy are limited. The objective of this article is to review the origins of the controversy regarding the current use of selective serotonin reuptake inhibitors (SSRIs) in children and adolescents. Two chief concerns drive the controversy: 1) the discovery of an increased risk of suicidal behaviors in those treated with SSRIs and 2) the efficacy of SSRIs in childhood and adolescent major depression is unclear. Various factors may account for the reported differences in outcomes for SSRI treatment in children and adolescents compared to adults. The past decade has shown a significant drop in the rate of adolescent suicide, which coincides with the onset of the use of these medications. Therefore, a reduction in the use of SSRIs in children and adolescents should be considered carefully.
authors.affiliation: clinneurochemist@msn.com
authors.forename: Elizabeth B
authors.initials: EB
authors.lastname: Weller
authors.forename: Sheridan
authors.initials: S
authors.lastname: Tucker
authors.forename: Ronald A
authors.initials: RA
authors.lastname: Weller
mesh_terms: D000293:Adolescent; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D000075202:Contraindications; D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D012306:Risk; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013405:Suicide / Q000706:statistics & numerical data; D016896:Treatment Outcome; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration; D000092864:Suicide Prevention
chemical_list: D018687:Antidepressive Agents, Second-Generation; D017367:Selective Serotonin Reuptake Inhibitors